Now showing items 1-1 of 1

    • Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. 

      James, N D; de Bono, J S; Spears, M R; Clarke, NW; Mason, M D; Dearnaley, D P; Ritchie, A W S; Amos, C L; Gilson, C; Jones, R J; Matheson, D; Millman, R; Attard, G; Chowdhury, S; Cross, W R; Gillessen, S; Parker, C C; Russell, J M; Berthold, D R; Brawley, C; Adab, F; Aung, San; Birtle, A J; Bowen, J; Brock, S; Chakraborti, P; Ferguson, C; Gale, J; Gray, E; Hingorani, M; Hoskin, P J; Lester, J F; Malik, Z I; McKinna, F; McPhail, N; Money-Kyrle, J; O'Sullivan, J; Parikh, O; Protheroe, A; Robinson, A; Srihari, N N; Thomas, C; Wagstaff, J; Wylie, J; Zarkar, A; Parmar, M K B; Sydes, M R (New England Journal of Medicine, 2017-07)
      Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using a multigroup, ...